Compare Amcor PLC (AMCR) vs Davita Inc (DVA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amcor PLC vs Davita Inc — how do they compare? Amcor PLC trades at $47.35 (market cap $21.78B), while Davita Inc trades at $179.02 (market cap $11.72B). The key difference: Amcor PLC is the larger of the two by market cap, and Amcor PLC pays a 5.52% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| AMCR | DVA | |
|---|---|---|
Market Cap | $21.78B | $11.72B |
Sector | Basic Materials | Health |
52-Week High | $50.58 | $240.96 |
52-Week Low | $36.69 | $103.87 |
Enterprise Value | $36.90B | $24.44B |
Dividend Yield | 5.52% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMCR trades at $47.86, up 1.7% today, near the consensus price target of $47.00. The stock shows bullish technical signals from moving averages, with RSI indicating mild overbought conditions. Recent quarters saw earnings beats, with Q2 2026 EPS expected at $1.19. Revenue grew to $15.01B in 2025, though net income margin declined to 3.06%. The company expanded its packaging facility in China and partnered with Kelpi for sustainable solutions, signaling growth initiatives.
Outlook is cautiously optimistic with analyst consensus at Buy (64%), but risks include margin pressure and high P/E of 38.44. Investment appeal hinges on earnings delivery and cost management amid competitive and macroeconomic headwinds.
DaVita (DVA) trades at $183.77, up 1.72% today, with a mixed technical picture showing bearish moving averages but bullish oscillators. The company reported strong Q2 2026 earnings of $4.02 per share, beating estimates, driven by volume growth. Revenue reached $13.64 billion in 2025, with a net income margin of 6.05%. Analyst consensus is a Buy with a $232.25 price target, though technical signals are bearish overall.
The outlook for DVA is cautiously optimistic, supported by earnings beats and volume growth, but risks include reimbursement pressure and high debt levels. The stock offers potential upside to the consensus target, yet investors face headwinds from margin compression and technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amcor PLC
Amcor is a global plastics packaging behemoth, with global sales of USD 14.5 billion in fiscal 2022 following the acquisition of Bemis in 2019. Amcor's operations span over 40 countries globally and include significant emerging-market exposure equating to circa 20% of sales. Amcor's capabilities span flexible and rigid plastic packaging, which sell into defensive food, beverage, healthcare, household, and personal-care end markets.
Read more on AMCR →About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →
